| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Mitochondrial membrane potential is disrupted by ipratropium bromide hydrate (1 nM, 10 nM, 100 nM; 15 minutes) to produce lethal effects [1]. In ischemia/reperfusion experiments in isolated perfused hearts, ipratropium bromide hydrate (1 nM-1 μM; 4 hours) increases infarct size in a dose-response manner (EC50=22.7 nM) [1]. After four hours of hypoxia, adult rat cardiomyocytes are inhibited in their ability to develop by ipratropium bromide hydrate (0.001 nM-0.1 mM; 2 hours) [1].
|
|---|---|
| ln Vivo |
Bronchoconstriction is caused by ipratropium bromide hydrate (1.0 μg/kg; IV; single dose), which amplifies vagal nerve stimulation [2]. The effects of induced acute neutrophilic inflammation are mitigated by ipratropium bromide hydrate (0.04 mg/20 mL and 0.20 mg/20 mL; inhalation over 30 minutes, rate=30 mL/30 minutes), which protects the lungs against cadmium. 4].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: adult rat cardiomyocytes Tested Concentrations: 0.001 nM-0.1 mM Incubation Duration: 2 hrs (hours) in the dark; 4 hrs (hours) before hypoxia Experimental Results: Cell viability was dose-dependent, and the inhibition rate was at the 0.1 mM dose 52.7%. |
| Animal Protocol |
Animal/Disease Models: Dunkin Hartley strain guinea pig [2]
Doses: 0.1-1 μg/kg Route of Administration: intravenous (iv) (iv)injection; intravenous (iv) (iv)injection. Single dose Experimental Results: 0.3 μg/kg had little blocking effect on postligation muscarinic receptors, and 0.5 μg/kg inhibited ACh-induced bronchoconstriction. Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rat (300-350 g) [4] Doses: 0.04 mg/20 mL and 0.20 mg/20 mL Route of Administration: Inhalation; Inhalation; Nebulization rate 30 mL/30 minutes; 30 minute Experimental Results: Has no significant effect on any parameters recorded in healthy rats, but has a protective effect on cadmium-induced inflammatory responses. |
| References |
|
| Additional Infomation |
Ipratropium bromide hydrate is the monohydrate form of ipratropium bromide. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulmonary disease and acute asthma. It has a role as a muscarinic antagonist and a bronchodilator agent. It contains an ipratropium bromide.
A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. See also: Ipratropium Bromide (annotation moved to). |
| Molecular Formula |
C20H32BRNO4
|
|---|---|
| Molecular Weight |
430.3764
|
| Exact Mass |
413.156
|
| CAS # |
66985-17-9
|
| Related CAS # |
Ipratropium bromide;22254-24-6;Ipratropium-d3 bromide;Ipratropium-d7 bromide
|
| PubChem CID |
16738693
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.026
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
[Br-].O(C(C([H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])O[H])=O)C1([H])C([H])([H])C2([H])C([H])([H])C([H])([H])C([H])(C1([H])[H])[N+]2(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])[H].O([H])[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~145.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (116.18 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3235 mL | 11.6176 mL | 23.2353 mL | |
| 5 mM | 0.4647 mL | 2.3235 mL | 4.6471 mL | |
| 10 mM | 0.2324 mL | 1.1618 mL | 2.3235 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
